Other Information Technology · Wilmington, DE · Founded 2024 · Privately Held (backing)
Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development. Converge Bio is based in Wilmington, DE and was founded in 2024. It was valued at $90 million at its early-stage round in Jan 2026, the last priced event on record. It has raised $30.5 million across 1 recorded round; the latest was a $25 million Series A in Jan 2026.
PMV mark · valuation
$90.0M
Oct 2026
Priced at
its early-stage round
Jan 2026
Total raised
$30.5M
Last round
Early Stage VC (Series A)
Jan 2026
No prints on record
No secondary trades in Converge Bio shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Converge Bio with a free account
·Watch Converge Bio: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Converge Bio stock.
